XII INTERNATIONAL WORKSHOP OF LOWER GENITAL TRACT PATHOLOGY

HPV diseases and cervical cancer: taking stock of the present and planning for the future.

Rome 5-7 March 2015

Course Directors
A. Frega, Italy
C. Gentili, Italy
P. Davies, Belgium
<table>
<thead>
<tr>
<th>Time</th>
<th>Room A</th>
<th>Room B</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45 - 08:15</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Welcome</td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>HPV infection and cervical cancer</td>
<td>Free communications</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td>Cervical screening around the world. Current status and key challenges</td>
<td>Free communications</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>11:30 - 13:00</td>
<td>Challenges in cervical screening</td>
<td>Free communications</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>LUNCH</td>
<td>LUNCH</td>
</tr>
<tr>
<td>14:30 - 16:25</td>
<td>HPV disease of the lower genital tract for gynaecologists. First part</td>
<td>HPV disease of the lower genital tract for pathologists. First part</td>
</tr>
<tr>
<td>16:25 - 16:45</td>
<td>Vaccination. Part one</td>
<td>Molecular tests in the cytopathology lab</td>
</tr>
<tr>
<td>16:45 - 17:40</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>17:40 - 18:35</td>
<td>New frontiers in colposcopy</td>
<td>Liquid-based cytology</td>
</tr>
<tr>
<td>17:55 - 18:35</td>
<td>Challenging situations in colposcopy</td>
<td>New issues in cytophology</td>
</tr>
<tr>
<td>18:35 - 18:53</td>
<td>Twitter session</td>
<td>Twitter session</td>
</tr>
</tbody>
</table>
### Friday 6 March

<table>
<thead>
<tr>
<th>Time</th>
<th>ROOM A</th>
<th>ROOM B</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:00</td>
<td>Clinical and pathology perspectives. The actors speak. Part one</td>
<td>Free communications</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>Atelier de travail</td>
<td>Atelier de travail</td>
</tr>
<tr>
<td>15:15 - 16:15</td>
<td>Vaccination. Part two</td>
<td>Classifications and quality control in cervical cytopathology</td>
</tr>
<tr>
<td>15:45 - 16:15</td>
<td>Management of CIN</td>
<td>Pap-smear: never say never again</td>
</tr>
<tr>
<td>16:15 - 16:45</td>
<td>BREAK</td>
<td>BREAK</td>
</tr>
<tr>
<td>16:45 - 17:15</td>
<td>Issues in colposcopy</td>
<td>Diagnosis in cytopathology</td>
</tr>
<tr>
<td>17:15 - 18:30</td>
<td>Multifocal diseases</td>
<td>Legal questions</td>
</tr>
<tr>
<td>18:30 - 18:54</td>
<td>Twitter session</td>
<td>Twitter session</td>
</tr>
</tbody>
</table>

### Saturday 7 March

<table>
<thead>
<tr>
<th>Time</th>
<th>ROOM A</th>
<th>ROOM B</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:00</td>
<td>HPV disease of the lower genital tract for gynaecologists. Third part</td>
<td>HPV disease of the lower genital tract for pathologists. Third part</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Issues in clinic</td>
<td>Focus on glandular lesions</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>Training in colposcopy</td>
<td>Training in cytopathology</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>ECM TEST</td>
<td>ECM TEST</td>
</tr>
<tr>
<td>12:00 - 12:45</td>
<td>Awards and conclusions</td>
<td></td>
</tr>
<tr>
<td>12:45 - 13:15</td>
<td>HPV disease: conclusions in twitter style</td>
<td></td>
</tr>
<tr>
<td>13:15 - 13:30</td>
<td>Closing ceremony</td>
<td></td>
</tr>
</tbody>
</table>
Thursday 5 March

08:15-08:30  WELCOME  
A. Frega, C. Gentili

PLENARY SESSION

08:30-09:00  HPV INFECTION AND CERVICAL CANCER  
A. Frega, C. Gentili

The natural history of HPV infection: “What’s happening, brother?”  
M.T. Goodman

What do the natural history studies tell us about the mechanisms of progression vs regression and does this help clinical decision-making?  
B. Moscicki

09:00-11:00  CERVICAL SCREENING AROUND THE WORLD. CURRENT STATUS AND KEY CHALLENGES  
P. Davies, P. Giorgi Rossi

Cervical screening outside of Europe  
09:00-09:15 North America  
R. Nayar

09:15-09:30 South America  
S. Tatti

09:30-09:45 Asia  
R. Sankaranarayanan

09:45-10:00 Australasia  
M. Saville

Cervical screening in Europe and the Caucasus  
10:00-10:20 Western Europe  
H. Sancho-Garnier

10:20-10:40 Eastern Europe  
D. Valuta

10:40-11:00 The Caucasus  
T. Khomasuridze

11:00-11:30 BREAK

11:30-13:00  CHALLENGES IN CERVICAL SCREENING  
L. Mariani, S. Tatti

11:30-11:45 Encouraging countries to move from opportunistic to organised screening  
P. Davies

11:45-12:00 The introduction of HPV testing for primary screening. Feedback from the first organised programmes  
N. Van der Veen

12:00-12:15 Can self-sampling improve screening efficacy among populations with low-screening attendance?  
H. Sancho-Garnier

12:15-12:30 Screening vaccinated populations. As disease rates decline, will screening cause more harm than good?  
P. Nieminen

12:30-12:45 HPV RNA testing: can it improve the screening algorithm?  
K.U. Petry

12:45-13:00 DISCUSSION

13:00-14:30 LUNCH

ROOM A

ECM COURSE: HPV DISEASE OF THE LOWER GENITAL TRACT FOR GYNAECOLOGISTS. FIRST PART

14:30-16:25  VACCINATION. PART ONE  
A. Lukic, J. Paavonen

HPV vaccination around the world. The programmes, the coverage and the challenges  
14:30-14:42 Europe and the Caucasus  
D. Valuta

14:42-14:54 North America  
R. Nayar

14:54-15:06 South America  
S. Tatti

15:06-15:18 Asia  
R. Sankaranarayanan

15:18-15:30 Australasia  
M. Saville

15:30-15:45 Planning a successful HPV vaccination launch: the key elements for success  
J. Dillner

15:45-16:00 HPV vaccination implementation case study: the Dutch experience  
M. Conyn-van Spaendonck

16:00-16:15 Vaccination: so how long does the protection really last?  
J. Dillner

16:15-16:25 DISCUSSION

16:25-16:45 BREAK

16:45-17:40  NEW FRONTIERS IN COLPOSCOPY  
K.U. Petry, F. Sesti

16:45-17:00 Colposcopy and HPV primary screening: clinical considerations  
P. Walker

17:00-17:15 Colposcopy in vaccinated populations: how to maintain performance as disease rates decline  
J. Paavonen

17:15-17:30 The use of HPV-related biomarkers in different clinical applications  
M. Kyrgiou

17:30-17:40 DISCUSSION
Thursday 5 March

17:40-18:35 CHALLENGING SITUATIONS IN COLPOSCOPY
A. Biamonti, P. Walker

17:40-17:55 Colposcopy in pregnancy: balancing the risk of pregnancy loss against cancer development
S. Dexeus

17:55-18:10 Colposcopy in menopause: challenges and solutions
K.U. Petry

18:10-18:25 Colposcopy: do we need more evidence-based training, standards and QA or just random biopsies?
W. Prendiville

18:25-18:35 DISCUSSION

18:35-18:53 TWITTER SESSION
F. Sesti, A. Lukic

18:35-18:41 Vaccination. Part one
J. Dillner

18:41-18:47 New frontiers in colposcopy
K.U. Petry

18:47-18:53 Challenging situations in colposcopy
P. Walker

FREE COMMUNICATIONS

08:30-09:40 CERVICAL CANCER AND HPV
D. French, A. Venuti

08:30-08:40 Autophagy is down-regulated by the E5 protein of human papillomavirus 16
M. Nanni, F. Belleudi, S. Rafia, M.R. Torrisi

08:40-08:50 Epithelial target cell and the development of cervical disease - current thinking and observations
R. Olaf, R. Sigrid

08:50-09:00 MicroRNA 551-b expression profile in cervical intraepithelial lesions

09:00-09:10 HPV16 E5 as target of immunotherapy
F. Paolini, M. Nazario Cordeiro, R. de Cássia Pereira de Lima, G. Curzio, A.C. de Freitas, A. Venuti

09:10-09:20 Human Papilloma Virus infection and his correlation with female parameters
N. Grieco, M.A. Di Filippo, T. Notari, G. D’Aniello, S. Ronsini

09:20-09:30 The sumo conjugating enzyme ubc9 as a biomarker for cervical HPV infections
C. Casadio, D. Mattoscio, M. Fumagalli, M. Sideri, S. Chiocca

09:30-09:40 New prospect in HPV infection therapy
P. Eid

09:40-10:00 P16/INK4a/ki-67 detection in ASC-US and ASC-H cytology with HR-HPV DNA positive test and in corresponding histological sample: preliminary data

10:00-10:10 Cervical Glandular Neoplasia and its look-a-like
S. Rahimi, S. Kenward, I. Akaev, S. Votano

10:10-10:20 Incidence of HR HPV and histological alterations in Pap-test with ASC-US
A. Berjawi Charour, N. Prats Montejano, G. Valdelvira Riego, M. Alsina Hipólito, Echavarría Ramos Maria del Carmen, E. Rodero Salgueiro

10:20-10:30 Comparative evaluation of RNA and DNA approach for HPV diagnosis
M. Piovan, A. Apolloni, T. Bartolotti, C. Lapucci

10:30-10:40 Novel flow cytometry-based assay for detection of E6/E7 mRNA in cervical and anal specimens
M. Mira, J. Coleman, D. Schapfel

10:40-10:50 Validation of in-house liquid based medium for HPV detection with Hybrid Capture 2

10:50-11:00 Assessment of Pap-smear quality
Sakonlaya Dussadee, Yanagihara Luckakul

11:00-11:30 BREAK

11:30-11:50 MOLECULAR AND MORPHOLOGIST DIAGNOSIS
S. Votano, A. Frega

11:30-11:40 Non Hodgkin lymphoma some features on the Pap-smear
C. Bosco, A. Chiarugi, S. Cuccato, P. Vicacca

11:40-11:50 HPV-mRNA test and multiple intraepithelial neoplasias of the female lower genital tract
G.N. Milazzo, A. Catalano, D. French, D. Caserta

17:40-18:35 CHALLENGING SITUATIONS IN COLPOSCOPY
A. Biamonti, P. Walker

17:40-17:55 Colposcopy in pregnancy: balancing the risk of pregnancy loss against cancer development
S. Dexeus

17:55-18:10 Colposcopy in menopause: challenges and solutions
K.U. Petry

18:10-18:25 Colposcopy: do we need more evidence-based training, standards and QA or just random biopsies?
W. Prendiville

18:25-18:35 DISCUSSION

18:35-18:53 TWITTER SESSION
F. Sesti, A. Lukic

18:35-18:41 Vaccination. Part one
J. Dillner

18:41-18:47 New frontiers in colposcopy
K.U. Petry

18:47-18:53 Challenging situations in colposcopy
P. Walker

ROOM B

FREE COMMUNICATIONS

08:30-09:40 CERVICAL CANCER AND HPV
D. French, A. Venuti

08:30-08:40 Autophagy is down-regulated by the E5 protein of human papillomavirus 16
M. Nanni, F. Belleudi, S. Rafia, M.R. Torrisi

08:40-08:50 Epithelial target cell and the development of cervical disease - current thinking and observations
R. Olaf, R. Sigrid

08:50-09:00 MicroRNA 551-b expression profile in cervical intraepithelial lesions

09:00-09:10 HPV16 E5 as target of immunotherapy
F. Paolini, M. Nazario Cordeiro, R. de Cássia Pereira de Lima, G. Curzio, A.C. de Freitas, A. Venuti

09:10-09:20 Human Papilloma Virus infection and his correlation with female parameters
N. Grieco, M.A. Di Filippo, T. Notari, G. D’Aniello, S. Ronsini

09:20-09:30 The sumo conjugating enzyme ubc9 as a biomarker for cervical HPV infections
C. Casadio, D. Mattoscio, M. Fumagalli, M. Sideri, S. Chiocca

09:30-09:40 New prospect in HPV infection therapy
P. Eid
Thursday 5 March

11:50-12:40 EPIDEMIOLOGY, SCREENING AND PROGNOSTIC FACTORS
  G. Petricone, M. Benevolo

11:50-12:00 HPV multiple infections, viral load and integration status: prognostic factors in secondary screening of cervical cancer

12:00-12:10 Primary HPV test in cervical cancer screening in local health unit of Latina (Italy)

12:10-12:20 The 16, 18 and 45 HPV infection triage in primary HR-HPV test screening program in local health unit of Latina (Italy)

12:20-12:30 Cervical cancer screening and cervical excisional treatment among women aged below 25 years between 2007 and 2013 in France
  I. Heard, C. Chaingnot, G. Maura, A. Weil, F. Alta, P. Ricordeau

12:30-12:40 Cervical Cancer
  O. Nöoeighöowa

12:40-13:10 EDUCATION AND AWARENESS
  A. Lukic, P. Scirpa

12:40-12:50 Perception about cervical cancer prevention of daughters in Korean mothers
  K. Hae Won

12:50-13:00 Primary prevention of HPV infection for adolescents
  L. Dubravko

13:00-13:10 Mediation effects of fear of cancer recurrence on cancer distress and quality of life in cervical cancer patients
  T. Shion-Luan, H. Chia-Ching

13:10-14:30 LUNCH

ECM COURSE: HPV DISEASE OF THE LOWER GENITAL TRACT FOR PATHOLOGISTS.
FIRST PART

14:30-16:25 MOLECULAR TESTS IN THE CYTOPATHOLOGY LAB
  T.M. Darragh, D. French

14:30-14:45 Getting around in molecular testing jungle: what clinicians and pathologists should know to properly interpret the results
  L. Dillner

14:45-15:00 Molecular tests: which tests are ready for clinical use and what do they add to clinical algorithms?
  M. Kyrgiou

15:00-15:15 HPV typing: do we know enough to base clinical decisions on HPV type (... or would we treat a woman with HPV 16 differently from a woman with HPV 33?)
  K.U. Petry

15:15-15:30 HPV E5 oncoprotein: possible role in L-SIL progression
  A. Venuti

15:30-15:45 Molecular bio-banking: a resource for research
  L. Dillner

15:45-16:00 What has changed in cytopathologist's report?
  M. Desai

16:00-16:25 DISCUSSION

16:25-16:45 BREAK

16:45-17:55 LIQUID-BASED CYTOLOGY
  C. Bergeron, G. Negri

16:45-17:15 The traditional Pap-test vs LBC. Two advocates present their cases
  L. Di Bonito, R. Nayar

17:15-17:30 LBC: a comparison of the systems
  M. Desai

17:30-17:45 Automation: can we afford it in these times of austerity?
  M. Saville

17:45-17:55 DISCUSSION

17:55-18:35 NEW ISSUES IN CYTOPATHOLOGY
  M. Benevolo, M. Desai

17:55-18:05 The Bethesda 2014 update: what’s new?
  R. Nayar

18:05-18:20 Cytology and HPV testing in the prevention of anal cancer
  T.M. Darragh

18:20-18:35 DISCUSSION

18:35-18:53 TWITTER SESSION
  L. Di Bonito

18:35-18:41 Molecular tests in the cytopathology lab
  L. Dillner

18:41-18:47 LBC
  G. Negri

18:47-18:53 New issues in cytopathology
  M. Saville
Friday 6 March

ROOM A

PLENARY SESSION

08:30-10:00 CLINICAL AND PATHOLOGY PERSPECTIVES. THE ACTORS SPEAK. PART ONE
A. Biamonti, G.L. Taddei

Cervical cytology or the molecular model: which is the best way forward?
08:30-08:40 Clinical perspective
P. Nieminen
08:40-08:50 Cytopathology perspective
R. Nayar
08:50-09:00 OPEN DISCUSSION

ASC-US and AGC: can we get over this deadlock?
09:00-09:10 Clinical perspective
P. Walker
09:10-09:20 Cytopathology perspective
G. Negri
09:20-09:30 OPEN DISCUSSION

CIN 2. Where are we now: do we treat it or not?
09:30-09:40 Clinical perspective
B. Moscicki
09:40-09:50 Cytopathology perspective
T.M. Darragh
09:50-10:00 OPEN DISCUSSION

10:00-10:30 BREAK

10:30-13:00 CLINICAL AND PATHOLOGY PERSPECTIVES. THE ACTORS SPEAK. PART TWO
A. Lukic, G.L. Taddei

Persistently HPV positive but cytology and colposcopy negative: what are the clinical recommendations?
10:30-10:40 Cytopathology perspective
M. Saville
10:40-10:50 Clinical perspective
W. Prendiville
10:50-11:00 OPEN DISCUSSION

HSIL but clinically normal: who is wrong?
11:00-11:10 Cytopathology perspective
M. Desai
11:10-11:20 Clinical perspective
K.U. Petry
11:20-11:30 OPEN DISCUSSION

Combining molecular tests: can this improve clinical decisions?
11:30-11:40 Cytopathology perspective
C. Bergeron
11:40-11:50 Clinical perspective
M. Kyrgiou
11:50-12:00 OPEN DISCUSSION

What can and can’t the pathologist say to clinician and the clinician to the pathologist?
12:00-12:10 Cytopathology perspective
L. Di Bonito
12:10-12:20 Clinical perspective
S. Dexeus
12:20-12:30 OPEN DISCUSSION

Revised terminology for cervical histopathology and its implications for management of HSIL
12:30-12:40 Pathology perspective
T.M. Darragh
12:40-12:50 Clinical perspective
S. Tatti
12:50-13:00 OPEN DISCUSSION

13:00-14:15 LUNCH

ECM COURSE: HPV DISEASE OF THE LOWER GENITAL TRACT FOR GYNAECOLOGISTS.
SECOND PART

14:15-15:15 VACCINATION: PART TWO
R. De Vincenzo, E. Siegler
14:15-14:30 HPV vaccination: three doses, two doses or just one?
R. Sankaranarayanan
14:30-14:45 What is the most cost-effective target population? Girls? Boys? Women? Men? Everybody?
J. Dillner
14:45-15:00 New developments in HPV vaccination: what do we know about the nonavalent vaccine?
J. Paavonen
15:00-15:15 DISCUSSION

15:15-16:15 MANAGEMENT OF CIN
B. Moscicki, P. Scirea
15:15-15:30 Clinical guidelines vs. clinical judgement: where do you draw the line?
P. Walker
15:30-15:45Treating CIN during pregnancy: key criteria and treatment options
E. Siegler
15:45-16:00 Treating recurrent CIN while preserving fertility in the nulliparous younger woman
M. Kyrgiou
16:00-16:15 DISCUSSION
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:10</td>
<td>Measurement of Quality of Colposcopy</td>
<td>C. Carriero, S. Leeson, F. Boselli</td>
<td>Quality Assurance of Colposcopy Italian Network (QuACINet)</td>
</tr>
<tr>
<td>09:10-09:20</td>
<td>Fertility and early pregnancy outcomes after treatment for cervical intra-epithelial neoplasia: a systematic review and meta-analysis of the literature</td>
<td>M. Kyrgiou, A. Mitra, M. Arbyn, S.M. Stasinou, P. Martin-Hirsch, P. Bennett, E. Paraskevadis</td>
<td>Management of patients with cytological low-grade or borderline abnormalities: how powerful is a negative colposcopy?</td>
</tr>
<tr>
<td>09:20-09:30</td>
<td>Management of patients with cytological low-grade or borderline abnormalities: how powerful is a negative colposcopy?</td>
<td>C. Ricci, M. Martin, K. Neenan, W. Prendiville</td>
<td></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-10:40</td>
<td>HPV TESTING AND VACCINATION</td>
<td>D. French, A. Biamonti</td>
<td></td>
</tr>
<tr>
<td>10:40-10:50</td>
<td>HPV-positive patients with the CIN relapse -further procedure and treatment</td>
<td>R. Živadinovic, A. Petric, D. Krtinic</td>
<td></td>
</tr>
<tr>
<td>10:50-12:00</td>
<td>CERVICAL CANCER PREVENTION IN LOW-RESOURCES SETTINGS</td>
<td>R. Sankaranarayanan, A. Venuti</td>
<td></td>
</tr>
<tr>
<td>10:50-11:00</td>
<td>Prevalence of human papilloma virus infection and cervical pre cancer lesions among female sex workers in Mumbai, India</td>
<td>P. Sharmila, M. Gauravi, S. Surendra</td>
<td></td>
</tr>
<tr>
<td>10:00-11:10</td>
<td>Development of HPV PCR assay in menstrual pad for rural Indian women: Pilot study data. Experience while standardizing method</td>
<td>P. Vrushali, B. Atul, M. Perveen, L. Manoj, M. Amrita, P. NS, P. Palllavi, D. Rajesh, V. Ashok</td>
<td></td>
</tr>
<tr>
<td>11:30-11:40</td>
<td>Comparative evaluation of Hybrid Capture 2 and cytology as triage tests among VIA/ VILI screen positive women</td>
<td>M. Gauravi, S. Surendra, K. Sheetal</td>
<td></td>
</tr>
</tbody>
</table>
Friday 6 March

11:40-11:50 Population based screenings for cervical cancer: cost effective approach in low resource setting using high end methodology in triaging algorithm and genomic integrations
   N. Manu, A. Maninder
11:50-12:00 Chemopreventive effects of curcumin on cervical cancers and precancerous cells
   S. Dusadee, T. Pirath, P. Auragun, C. Saengsoon

12:00-12:40 MISCELLANEOUS
   M.T. Goodman, R. Senatori
   12:00-12:10 Characterization of the vaginal microbiome in women with cervical intraepithelial neoplasia
      A. Mitra, D. MacIntyre, L. Yun, A. Smith, J. Marchesi, E. Holmes, J. Nicholson, P. Bennett, M. Kyrgiou
   12:10-12:20 Impact of Sexually Transmitted Diseases in pregnancy: knowledge of pregnant women
      C. Caixeta
   12:20-12:30 Rare genitourinary anomalies
      M. Fahmy
   12:30-12:40 Prevalence of co-infections with human papillomavirus and mycoplasma/ureaplasma species in women with abnormal cervical cytology
      Ji Yong Il

12:40-13:00 LUNCH

ECM COURSE: HPV DISEASE OF THE LOWER GENITAL TRACT FOR PATHOLOGISTS. SECOND PART

14:15-15:15 CLASSIFICATIONS AND QUALITY CONTROL IN CERVICAL CYTOPATHOLOGY
   G. Negri, M. Saville
   14:15-14:35 Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection
      C. Bergeron
   14:35-14:55 Quality control in cervical cytology: can we exploit the biomarkers?
      M. Desai
   14:55-15:15 DISCUSSION

15:15-16:15 PAP-SMEAR: NEVER SAY NEVER AGAIN
   R. Nayar, A. Venuti
   15:15-15:30 Cervical cytology: can it survive in the era of HPV vaccination?
      C. Bergeron
   15:30-15:45 Why East European countries should still devote resources to the Pap-smear
      P. Davies

15:45-16:00 What molecular biology cannot provide
   G. Negri
   16:00-16:15 DISCUSSION

16:15-16:45 BREAK

16:45-17:15 DIAGNOSIS IN CYTOPATHOLOGY
   L. Di Bonito, T.M. Darragh
   16:45-17:00 Cytology accuracy: can more training compensate for time constraints?
      M. Saville
   17:00-17:15 Cytology during pregnancy: does it need to be interpreted differently depending on the stage of pregnancy?
      M. Desai
   17:15-17:30 Cytology in menopause: challenge for the pathologist
      G. Negri
   17:30-17:45 DISCUSSION

17:45-18:30 LEGAL QUESTIONS
   G. Negri, M. Saville
   17:45-18:00 Over-diagnosis in cytopathology: is the histology the gold standard?
      T.M. Darragh
   18:00-18:15 Legal questions in the lab with the new molecular algorithms
      R. Nayar
   18:15-18:30 DISCUSSION

18:30-18:54 TWITTER SESSION
   M. Benevolo, T.M. Darragh
   18:30-18:36 Classifications and quality control in cervical cytology
      C. Bergeron
   18:36-18:42 Pap-smear: never say never again
      G. Negri
   18:42-18:48 Diagnosis in cytopathology
      L. Di Bonito
   18:48-18:54 Legal issues for the cytopathologist
      M. Desai
Saturday 7 March

ROOM A

ECM COURSE: HPV DISEASE OF THE LOWER GENITAL TRACT FOR GYNAECOLOGISTS.
THIRD PART

08:30-10:00  ATELIER DE TRAVAIL
G. Petricone, P. Stentella

Video interactive session on colposcopy coordinated by Walter Prendiville
M. Barbero, A. Biamonti, S. Dexeus, K.U.Petry, S. Tatti, P. Nieminen

10:00-10:30  ISSUES IN CLINIC
C. Carriero, S. Votano

10:00-10:15  Challenge in menopause: improving diagnosis and treatment
F.M. Primiero

10:15-10:30  HR HPV genotypes on spermatozoa from male partners of infertile couples
A. Perino

10:30-10:45  BREAK

10:45-11:45  TRAINING IN COLPOSCOPY
F. Boselli, P. Inghiram

10:45-11:00  Minimal standards in colposcopy
M. Peroni

11:00-11:15  How to audit your colposcopy practice
P. Cristoforoni

11:15-11:30  The nurse colposcopist: salvation or heresy?
W. Prendiville

11:30-11:45  DISCUSSION

11:45-12:00  ECM TEST

ROOM B

ECM COURSE: HPV DISEASE OF THE LOWER GENITAL TRACT FOR PATHOLOGISTS.
THIRD PART

08:30-10:00  ATELIER DE TRAVAIL
M.R. Giovagnoli, G.F. Zannoni

Interactive slide seminar
L. Di Bonito, G. Negri

10:00-10:30  FOCUS ON GLANDULAR LESIONS
L. Di Bonito, G. Negri

10:00-10:15  Atypical glandular cells and its differential diagnosis from true lesions
M. Desai

10:15-10:30  Histological implication of Pap-smear classified as atypical glandular cell
G.F. Zannoni

10:30-10:45  BREAK

10:45-11:45  TRAINING IN CYTOPATHOLOGY
L. Di Bonito, G. Negri

10:45-11:00  The role of cytotecnican in the lab
C. Bosco

11:00-11:15  How can I update myself: courses, books, e-learning, DIY (do it yourself)…?
M.R. Giovagnoli

11:15-11:30  How to audit my own practice
M. Desai

11:30-11:45  DISCUSSION

11:45-12:00  ECM TEST

PLENARY SESSION

12:00-12:45  AWARDS AND CONCLUSIONS
A. Frega, C. Gentili

12:00-12:30  PRESENTATION AND AWARDING OF THE THREE BEST COMMUNICATIONS

12:30-12:45  AWARDING OF THE THREE BEST SPEAKERS

12:45-13:15  HPV DISEASE. CONCLUSIONS IN TWITTER STYLE
R. Senatori, S. Votano

12:45-12:51  HPV infection and cervical cancer
L. Mattioni

12:51-12:57  Screening around the world
P. Davies

12:57-13:03  HPV vaccination
R. De Vincenzo

13:03-13:09  Colposcopy today
P. Walker

13:09-13:15  Cytology: quo vadis?
G. Negri

13:15-13:30  CLOSING CEREMONY
<table>
<thead>
<tr>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>M. Barbero</strong> Asti, Italy</td>
</tr>
<tr>
<td><strong>M. Benevolo</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>C. Bergeron</strong> Paris, France</td>
</tr>
<tr>
<td><strong>A. Biamonti</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>C. Bosco</strong> Viareggio, Italy</td>
</tr>
<tr>
<td><strong>F. Boselli</strong> Modena, Italy</td>
</tr>
<tr>
<td><strong>C. Carriero</strong> Bari, Italy</td>
</tr>
<tr>
<td><strong>M. Conyn-van Spaendonck</strong> Bilthoven, The Netherlands</td>
</tr>
<tr>
<td><strong>P. Cristoforoni</strong> Genoa, Italy</td>
</tr>
<tr>
<td><strong>T.M. Darragh</strong> San Francisco, U.S.</td>
</tr>
<tr>
<td><strong>P. Davies</strong> Brussels, Belgium</td>
</tr>
<tr>
<td><strong>R. De Vincenzo</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>M. Desai</strong> Manchester, UK</td>
</tr>
<tr>
<td><strong>S. Dexeus</strong> Barcelona, Spain</td>
</tr>
<tr>
<td><strong>L. Di Bonito</strong> Trieste, Italy</td>
</tr>
<tr>
<td><strong>J. Dillner</strong> Malmo, Sweden</td>
</tr>
<tr>
<td><strong>L. Dillner</strong> Stockholm, Sweden</td>
</tr>
<tr>
<td><strong>A. Frega</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>D. French</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>C. Gentili</strong> Carrara, Italy</td>
</tr>
<tr>
<td><strong>P. Giorgi Rossi</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>M.R. Giovagnoli</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>M.T. Goodman</strong> Los Angeles, U.S.</td>
</tr>
<tr>
<td><strong>P. Inghirami</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>T. Khomasuridze</strong> Istanbul, Turkey</td>
</tr>
<tr>
<td><strong>M. Kyrgiou</strong> London, UK</td>
</tr>
<tr>
<td><strong>A. Lukic</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>L. Mariani</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>L. Micheletti</strong> Turin, Italy</td>
</tr>
<tr>
<td><strong>B. Moscicki</strong> San Fransisco, U.S.</td>
</tr>
<tr>
<td><strong>O. Nappi</strong> Naples, Italy</td>
</tr>
<tr>
<td><strong>R. Nayar</strong> Evanston, U.S.</td>
</tr>
<tr>
<td><strong>G. Negri</strong> Bolzano, Italy</td>
</tr>
<tr>
<td><strong>P. Nieminen</strong> Helsinki, Finland</td>
</tr>
<tr>
<td><strong>J. Paavonen</strong> Helsinki, Finland</td>
</tr>
<tr>
<td><strong>A. Perino</strong> Palermo, Italy</td>
</tr>
<tr>
<td><strong>M. Peroni</strong> Ascoli Piceno, Italy</td>
</tr>
<tr>
<td><strong>G. Petricone</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>K.U. Petry</strong> Wolsfburg, Germany</td>
</tr>
<tr>
<td><strong>W. Prendiville</strong> Lyon, France</td>
</tr>
<tr>
<td><strong>F.M. Primiero</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>H. Sancho-Garnier</strong> Montpellier, France</td>
</tr>
<tr>
<td><strong>R. Santharanarayanan</strong> Lyon, France</td>
</tr>
<tr>
<td><strong>M. Saville</strong> Victoria, Australia</td>
</tr>
<tr>
<td><strong>P. Scirpa</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>R. Senatori</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>F. Sesti</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>E. Siegler</strong> Haifa, Israel</td>
</tr>
<tr>
<td><strong>P. Stentella</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>G.L. Taddei</strong> Florence, Italy</td>
</tr>
<tr>
<td><strong>S. Tatti</strong> Buenos Aires, Argentina</td>
</tr>
<tr>
<td><strong>D. Valuta</strong> Chisinau, Moldova</td>
</tr>
<tr>
<td><strong>N. Van der Veen</strong> Bilthoven, The Netherlands</td>
</tr>
<tr>
<td><strong>A. Venuti</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>S. Votano</strong> Rome, Italy</td>
</tr>
<tr>
<td><strong>P. Walker</strong> London, UK</td>
</tr>
<tr>
<td><strong>C. Zanardi</strong> Bologna, Italy</td>
</tr>
<tr>
<td><strong>G.F. Zannoni</strong> Rome, Italy</td>
</tr>
</tbody>
</table>
General Information

CONGRESS VENUE
Ergife Palace Hotel
Via Aurelia, 619
00165 - Rome

LANGUAGE
The official language of the Workshop is English. Simultaneous translation into Italian will be provided.

ECM ACCREDITATION
During the Congress there will be two ECM Courses, one in Room A and one in Room B. The two courses will be simultaneous and will last three days (2 afternoon Sessions and 1 morning Session each). To obtain the credits is necessary to attend only one course, follow the 100% of the training activity and to exceed the questions proposed by the follow-up test. The effective attendees will be verified by signature of the dedicated records at the time of entrance and exit. Partial and missing survey of participation to the convention works, will not allow ECM accreditation. ECM Test will be distributed by hostesses. Participants will duly have to fill them in, sign and return them to the Secretariat.

The Course “HPV DISEASE OF THE LOWER GENITAL TRACT FOR GYNAECOLOGISTS” has been accredited for 5,5 ECM credits (712-114514).

The Course “HPV DISEASE OF THE LOWER GENITAL TRACT FOR PATHOLOGISTS” has been accredited for 5,5 ECM credits (712-114550).

The specialties and disciplines able to apply for Italian ECM credits are:
- Medico Chirurgo/Surgeon (Anatomia Patologica; Igiene, epidemiologia e sanità pubblica; Ginecologia e Ostetricia; Oncologia; Patologia clinica (laboratorio di analisi chimico-cliniche e microbiologia));
- Biologo/Biologist (Anatomia Patologica; Igiene, epidemiologia e sanità pubblica; Patologia clinica (Laboratorio di analisi chimico-cliniche e microbiologia));
- Tecnici di laboratorio biomedico/ Biomedical laboratory technicians.

National educational aim n. 1: Applicazione nella pratica quotidiana dei principi e delle procedure dell’evidence based practice/Application in the daily practice of the principles and procedures of the evidence based practice.

PARTICIPANTS RECRUITMENT
On the 18th of January 2011 the National ECM commission defined: Sanitary professionals can use direct sponsorships by agencies till 50 ECM credits out of the 150 ECM credits to be acquired throughout three years 2014/16 with the registration of the order of belongings. The credit certificate will be checked out by COSEAPS and orders, associations where the professional is registered till the greater quote of 1/3.

LOCAL ORGANIZING COMMITTEE
Alberto Biamonti, Italy
Rosa De Vincenzo, Italy
Deborah Fréch, Italy
Giancarlo Petricone, Italy
Paolo Scirpa, Italy
Francesco Sesti, Italy
Sergio Votano, Italy

SCIENTIFIC COMMITTEE
Christine Bergeron, France
Mina Desai, UK
Joakim Dillner, Sweden
Ankica Lukic, Italy
Barbara Moscicki, U.S.
K. Ulrich Petry, Germany
Walter Prendiville, France
Patrick Walker, UK

ORGANIZING SECRETARIAT
Triumph Italy S.r.l.
Via Lucilio 60 - 00136 Rome
Phone: +39 06 35530 382
Fax: +39 06 35530 262
hpv2015rome@thetriumph.com
www.hpv2015rome.com

Provider n. 712

Triumph ECM S.r.l.
Via Lucilio, 60 – 00136 Rome